Literature DB >> 24408041

Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach.

Alfonso Di Costanzo1, Tommaso Scarabino, Francesca Trojsi, Teresa Popolizio, Simona Bonavita, Mario de Cristofaro, Renata Conforti, Adriana Cristofano, Claudio Colonnese, Ugo Salvolini, Gioacchino Tedeschi.   

Abstract

OBJECTIVE: The discrimination between recurrent glioma and radiation injury is often a challenge on conventional magnetic resonance imaging (MRI). We verified whether adding and combining proton MR spectroscopic imaging ((1)H-MRSI), diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) information at 3 Tesla facilitate such discrimination.
MATERIALS AND METHODS: Twenty-nine patients with histologically verified high-grade gliomas, who had undergone surgical resection and radiotherapy, and had developed new contrast-enhancing lesions close to the treated tumour, underwent MRI, (1)H-MRSI, DWI and PWI at regular time intervals. The metabolite ratios choline (Cho)/normal( n )Cho n , N-acetylaspartate (NAA)/NAA n , creatine (Cr)/Cr n , lactate/lipids (LL)/LL n , Cho/Cr n , NAA/Cr n , Cho/NAA, NAA/Cr and Cho/Cr were derived from (1)H-MRSI; the apparent diffusion coefficient (ADC) from DWI; and the relative cerebral blood volume (rCBV) from PWI.
RESULTS: In serial MRI, recurrent gliomas showed a progressive enlargement, and radiation injuries showed regression or no modification. Discriminant analysis showed that discrimination accuracy was 79.3 % when considering only the metabolite ratios (predictor, Cho/Cr n ), 86.2 % when considering ratios and ADC (predictors, Cho/Cr n and ADC), 89.7 % when considering ratios and rCBV (predictors, Cho/Cr n , Cho/Cr and rCBV), and 96.6 % when considering ratios, ADC and rCBV (predictors, Cho/Cho n , ADC and rCBV).
CONCLUSIONS: The multiparametric 3-T MR assessment based on (1)H-MRSI, DWI and PWI in addition to MRI is a useful tool to discriminate tumour recurrence/progression from radiation effects.

Entities:  

Mesh:

Year:  2014        PMID: 24408041     DOI: 10.1007/s11547-013-0371-y

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  41 in total

1.  Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.

Authors:  Xintao Hu; Kelvin K Wong; Geoffrey S Young; Lei Guo; Stephen T Wong
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

2.  Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.

Authors:  James R Fink; Robert B Carr; Eiji Matsusue; Ramesh S Iyer; Jason K Rockhill; David R Haynor; Kenneth R Maravilla
Journal:  J Magn Reson Imaging       Date:  2011-10-14       Impact factor: 4.813

3.  Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy.

Authors:  Alfonso Di Costanzo; Tommaso Scarabino; Francesca Trojsi; Giuseppe M Giannatempo; Teresa Popolizio; Domenico Catapano; Simona Bonavita; Nicola Maggialetti; Michela Tosetti; Ugo Salvolini; Vincenzo A d'Angelo; Giocchino Tedeschi
Journal:  Neuroradiology       Date:  2006-06-03       Impact factor: 2.804

4.  Quantifying radiation therapy-induced brain injury with whole-brain proton MR spectroscopy: initial observations.

Authors:  B Movsas; B S Li; J S Babb; B L Fowble; N Nicolaou; O Gonen
Journal:  Radiology       Date:  2001-11       Impact factor: 11.105

5.  Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.

Authors:  Jun-Ling Xu; Yong-Li Li; Jian-Min Lian; She-wei Dou; Feng-Shan Yan; Hui Wu; Da-peng Shi
Journal:  Neuroradiology       Date:  2010-06-23       Impact factor: 2.804

6.  Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery.

Authors:  E E Graves; S J Nelson; D B Vigneron; L Verhey; M McDermott; D Larson; S Chang; M D Prados; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

7.  Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy.

Authors:  H P Schlemmer; P Bachert; K K Herfarth; I Zuna; J Debus; G van Kaick
Journal:  AJNR Am J Neuroradiol       Date:  2001-08       Impact factor: 3.825

8.  Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas.

Authors:  R G Henry; D B Vigneron; N J Fischbein; P E Grant; M R Day; S M Noworolski; J M Star-Lack; L L Wald; W P Dillon; S M Chang; S J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

9.  Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo.

Authors:  T Usenius; J P Usenius; M Tenhunen; P Vainio; R Johansson; S Soimakallio; R Kauppinen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-10-15       Impact factor: 7.038

10.  Role of advanced MR imaging modalities in diagnosing cerebral gliomas.

Authors:  T Scarabino; T Popolizio; F Trojsi; G Giannatempo; S Pollice; N Maggialetti; A Carriero; A Di Costanzo; G Tedeschi; U Salvolini
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

View more
  24 in total

Review 1.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

Review 2.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

Review 3.  The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint.

Authors:  Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

Review 4.  Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours.

Authors:  Ananya Chakravorty; Timothy Steel; Joga Chaganti
Journal:  Neuroradiol J       Date:  2015-10-16

5.  Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous 18F-FDG-PET/MRI: A Single-Institution Retrospective Study.

Authors:  A Jena; S Taneja; A Jha; N K Damesha; P Negi; G K Jadhav; S M Verma; S K Sogani
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-24       Impact factor: 3.825

Review 6.  Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Eur Radiol       Date:  2018-01-26       Impact factor: 5.315

Review 7.  Current Clinical Brain Tumor Imaging.

Authors:  Javier E Villanueva-Meyer; Marc C Mabray; Soonmee Cha
Journal:  Neurosurgery       Date:  2017-09-01       Impact factor: 4.654

Review 8.  Choline metabolism-based molecular diagnosis of cancer: an update.

Authors:  Kristine Glunde; Marie-France Penet; Lu Jiang; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Expert Rev Mol Diagn       Date:  2015-04-28       Impact factor: 5.225

Review 9.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

Review 10.  Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma.

Authors:  Janine M Lupo; Sarah J Nelson
Journal:  Semin Radiat Oncol       Date:  2014-07-26       Impact factor: 5.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.